PYC Therapeutics (ASX:PYC) has announced that the Safety Review Committee governing the Phase 1 clinical trial of VP-001 being studied in Retinitis Pigmentosa type 11 has approved the escalation of dosing to patient cohort 3. …
PYC Therapeutics progressing to high dose patient cohort in RP11 trial
December 18, 2023 Australian Biotech
Latest Video
New Stories
-
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies
April 10, 2026 - - Australian Biotech -
Lower official co-payment but patients paying for more unsubsidised medicines
April 10, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 10 April
April 10, 2026 - - Podcast -
Is there any example of another review or inquiry taking this long?
April 10, 2026 - - Latest News -
Rewriting the rules of PBS negotiations to deliver a patient-first reset
April 10, 2026 - - Latest News -
A decade of readiness as AVITA medical expands burn response capability
April 9, 2026 - - Australian Biotech -
Moderna names Carolyn Tucek-Szabo to lead Australia and New Zealand operations
April 9, 2026 - - Latest News